GLP-1 Peptide CDMO & Manufacturing Capacity Market
完整報告名稱與涵蓋範圍
GLP-1 Peptide CDMO & Manufacturing Capacity Market Size, Share & Trends Analysis Report, By Service Type (Peptide API Manufacturing (Solid-Phase and Liquid-Phase Synthesis), Recombinant Peptide Production, Formulation and Sterile Fill-Finish, Pen and Autoinjector Assembly and Packaging, Analytical and Quality Services), By Molecule Type (Semaglutide and Liraglutide, Tirzepatide and Multi-Agonist Peptides, Oral Peptide Formulations, Pipeline and Generic GLP-1 Peptides), By Scale (Clinical Supply, Commercial Supply), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The GLP-1 peptide CDMO and manufacturing capacity market covers outsourced manufacturing services dedicated to GLP-1 and related incretin peptides, from active ingredient synthesis through formulation, sterile fill-finish and pen or autoinjector assembly, together with the analysis of global capacity, investment and supply chain constraints. Captive originator manufacturing is analysed for context but its output is not counted as CDMO revenue.
Unprecedented demand for semaglutide and tirzepatide has created persistent supply shortages, prompting multi-billion-dollar capacity programs by originators, acquisitions of fill-finish networks and long-term capacity reservations with peptide CDMOs. Solid-phase synthesis capacity, resin and protected amino acid supply, sterile cartridge filling lines and pen assembly have all become bottlenecks. Providers are adding large-scale synthesis suites, exploring liquid-phase and hybrid routes to cut cost and solvent use, and expanding device assembly, while impending generic entry and a broad pipeline of next-generation peptides will diversify the customer base beyond two innovators.
Europe and the United States host the leading peptide CDMOs and most new sterile capacity, while China and India are scaling low-cost API production aimed at generic and emerging-market supply. Competition involves specialist peptide manufacturers, diversified CDMOs, originator-owned capacity and Asian API producers.
The InsightAce study delivers revenue forecasts in US$ across all service type, molecule type, scale and end user and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global GLP-1 Peptide CDMO & Manufacturing Capacity Market Snapshot
Chapter 4. Global GLP-1 Peptide CDMO & Manufacturing Capacity Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Service Type Estimates & Trend Analysis
5.1. Service Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Service Type:
5.2.1. Peptide API Manufacturing (Solid-Phase and Liquid-Phase Synthesis)
5.2.2. Recombinant Peptide Production
5.2.3. Formulation and Sterile Fill-Finish
5.2.4. Pen and Autoinjector Assembly and Packaging
5.2.5. Analytical and Quality Services
Chapter 6. Market Segmentation 2: By Molecule Type Estimates & Trend Analysis
6.1. Molecule Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Molecule Type:
6.2.1. Semaglutide and Liraglutide
6.2.2. Tirzepatide and Multi-Agonist Peptides
6.2.3. Oral Peptide Formulations
6.2.4. Pipeline and Generic GLP-1 Peptides
Chapter 7. Market Segmentation 3: By Scale Estimates & Trend Analysis
7.1. Scale & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Scale:
7.2.1. Clinical Supply
7.2.2. Commercial Supply
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Innovator Pharmaceutical Companies
8.2.2. Generic and Biosimilar Manufacturers
8.2.3. Biotechnology Companies
Chapter 9. GLP-1 Peptide CDMO & Manufacturing Capacity Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Bachem Holding AG
11.2. PolyPeptide Group AG
11.3. CordenPharma International
11.4. Lonza Group AG
11.5. WuXi AppTec (WuXi TIDES)
11.6. AmbioPharm, Inc.
11.7. Thermo Fisher Scientific Inc. (Patheon)
11.8. Piramal Pharma Solutions
11.9. Novo Nordisk A/S (Catalent)
11.10. Hybio Pharmaceutical Co., Ltd.
11.11. Chengdu Shengnuo Biotec Co., Ltd.
11.12. ScinoPharm Taiwan, Ltd.
11.13. Vetter Pharma International GmbH
11.14. Ypsomed AG
11.15. Recipharm AB
圖表清單 List of Tables & Figures
Table 1. Global GLP-1 Peptide CDMO & Manufacturing Capacity Market Revenue Forecast by Service Type, 2026-2035 (US$ Mn)
Figure 1. Global GLP-1 Peptide CDMO & Manufacturing Capacity Market Segmentation Overview
Table 2. Global GLP-1 Peptide CDMO & Manufacturing Capacity Market Revenue Forecast by Molecule Type, 2026-2035 (US$ Mn)
Figure 2. Global GLP-1 Peptide CDMO & Manufacturing Capacity Market Share by Service Type, 2026 & 2035
Table 3. Global GLP-1 Peptide CDMO & Manufacturing Capacity Market Revenue Forecast by Scale, 2026-2035 (US$ Mn)
Figure 3. Global GLP-1 Peptide Synthesis and Fill-Finish Capacity Additions by Provider, 2024-2030
Table 4. Global GLP-1 Peptide CDMO & Manufacturing Capacity Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Global GLP-1 Peptide CDMO & Manufacturing Capacity Market Share by Molecule Type, 2026 & 2035
Table 5. North America GLP-1 Peptide CDMO & Manufacturing Capacity Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. GLP-1 Manufacturing Value Chain Bottlenecks from Raw Materials to Pen Assembly
Table 6. Europe GLP-1 Peptide CDMO & Manufacturing Capacity Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific GLP-1 Peptide CDMO & Manufacturing Capacity Growth Opportunity Analysis
Table 7. Asia Pacific GLP-1 Peptide CDMO & Manufacturing Capacity Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Cost Comparison of Solid-Phase, Liquid-Phase and Recombinant Peptide Routes at Commercial Scale
Table 8. Latin America GLP-1 Peptide CDMO & Manufacturing Capacity Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key GLP-1 Peptide CDMO & Manufacturing Capacity Market Participants
Table 9. Middle East & Africa GLP-1 Peptide CDMO & Manufacturing Capacity Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們